Trump's Psychedelics Executive Order Could Accelerate Stalled Cannabis Reform

President Trump signed an executive order on April 18 directing the Food and Drug Administration to prioritize and accelerate the regulatory review of psilocybin, MDMA, ibogaine, and ketamine for therapeutic medical applications — a move that researchers in the psychedelic-assisted therapy field called an unexpected breakthrough after years of progress that stalled when the FDA rejected MDMA-assisted therapy applications in 2024.

The executive order instructs the FDA to create an expedited review pathway for psychedelic-based treatments, designates psychedelic medicine research as a national priority, and allocates $50 million over two years from the Department of Health and Human Services discretionary budget to support clinical trials. The order specifically directs the FDA to convene an advisory committee within 90 days to provide guidance on trial design and approval standards for psychedelic treatments of post-traumatic stress disorder, treatment-resistant depression, and addiction disorders.

The administration's motivation, White House officials said, is primarily veterans' health. Trump has long positioned veteran mental health care as a signature issue, and multiple briefings from veteran service organizations have highlighted psychedelic-assisted therapy as a potentially transformative treatment for the estimated 20 percent of combat veterans who experience PTSD. The special operations community in particular has been vocal about the need for alternatives to existing pharmaceutical approaches that many veterans describe as insufficient or intolerable.

The political context makes the executive order striking. Trump's base includes many voters with strong anti-drug views, and the administration simultaneously maintains a hard line on recreational drug use. White House officials were careful to emphasize that the order applies exclusively to medical and therapeutic use under clinical supervision — not recreational decriminalization. The order contains explicit language stating that it "does not modify, relax, or affect the scheduling status of any controlled substance under the Controlled Substances Act."

However, the executive order's timing relative to ongoing cannabis rescheduling proceedings has drawn notice from drug policy analysts. The Drug Enforcement Administration's proposal to move marijuana from Schedule I to Schedule III, initiated during the Biden administration, remains pending in administrative proceedings. Critics of the Trump administration's drug policy have pointed out that prioritizing psychedelic medicine while declining to advance cannabis rescheduling is logically inconsistent, since psilocybin and MDMA remain Schedule I substances with no currently accepted medical use — the same legal status as marijuana.

Researchers at institutions including Johns Hopkins University, New York University, and UCSF who have conducted the major clinical trials for psilocybin-assisted therapy expressed cautious optimism about the executive order but noted that the 2024 FDA rejection of MDMA-assisted therapy reflected genuine scientific concerns about trial design and data integrity, not political opposition. Several said the $50 million allocation, while welcome, was insufficient to fund the large-scale Phase 3 trials required for full approval.

"This is a real signal that the administration wants to move on this," said Dr. Matthew Johnson of Johns Hopkins, who has led psilocybin research for over a decade. "But the science has to be done right, and the science takes time. Executive orders can't speed up proper randomized controlled trials."

The Multidisciplinary Association for Psychedelic Studies, whose MDMA research program was the furthest along before the 2024 rejection, said it was actively preparing a resubmission and hoped the new regulatory guidance framework would address the FDA's previous concerns.